预约演示

更新于：2025-05-16

Pilocarpine Hydrochloride

盐酸毛果芸香碱

更新于：2025-05-16

概要

基本信息

药物类型

小分子化药

别名

MicroLine、PILOCARPINE、pilocarpine 1.25%

+ [38]

靶点

mAChRs

作用方式

激动剂

作用机制

mAChRs激动剂(毒蕈碱型乙酰胆碱受体家族激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Romeg Therapeutics LLC

AbbVie, Inc.Novus Vision LLC

+ [10]

非在研机构

极目峰睿（上海）生物科技有限公司

Entod Pharmaceuticals Ltd.

Alcami Carolinas Corp.

+ [3]

权益机构

Eyenovia, Inc.常州极目生物科技有限公司

Orasis Pharmaceuticals Ltd.

+ [3]

最高研发阶段批准上市

首次获批日期

加拿大 (1951-12-31),

口干症

最高研发阶段(中国)临床前

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C11H17ClN2O2

InChIKeyRNAICSBVACLLGM-GNAZCLTHSA-N

CAS号54-71-7

关联

108

项与盐酸毛果芸香碱相关的临床试验

TCTR20250309013

/ Recruiting临床2期IIT

Efficacy of a new formulation of 0.2% pilocarpine spray in patients with hyposalivation

开始日期2025-03-05

申办/合作机构-

NCT06783686

/ Active, not recruiting早期临床1期

Effect on Pupil Size After One-time Administration of NV701 (Pilocarpine 1.25%) Vs. Vuity (Pilocarpine 1.25%)

Randomized contralateral eye study to evaluate the effect of one-time dosing of NV701 versus commercially available 1.25% pilocarpine solution on pupil size.

开始日期2025-01-30

申办/合作机构

Novus Vision LLC

CTR20244733

/ Recruiting临床3期

盐酸毛果芸香碱滴眼液用于成人老视患者的有效性和安全性的随机、多中心、双盲、安慰剂对照临床试验

以安慰剂为对照，评价盐酸毛果芸香碱滴眼液1.25%用于成人老视患者的有效性和安全性。

开始日期2024-12-24

申办/合作机构

北京福元医药股份有限公司

100 项与盐酸毛果芸香碱相关的临床结果

登录后查看更多信息

100 项与盐酸毛果芸香碱相关的转化医学

登录后查看更多信息

100 项与盐酸毛果芸香碱相关的专利（医药）

登录后查看更多信息

11,010

项与盐酸毛果芸香碱相关的文献（医药）

2025-08-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and biological evaluation of N-substituted nipecotamide derivatives as multifunctional agents for epilepsy treatment

Article

作者: Wang, Chao ; Ding, Yi ; Tian, Xin ; Li, Linrui ; Yuan, Yu ; Hong, Lijun ; Zhu, Jiang ; Cao, Zhongcheng ; Li, Wei

To discover novel multi-functional antiepileptic agents, nipecotamide was hybridized with salicylaldehyde, paeonol, vanillin and cinnamaldehyde to generate a series of N-substituted nipecotamide derivatives. Biological screening revealed that compound 11c exhibited remarkable scavenging activities against ABTS (2,2'-Azinobis-(3-ethylbenzthiazoline-6-sulfonic acid)) radical (scavenging IC₅₀: 92.0 μM), DPPH (1,1-Diphenyl-2-picrylhydrazyl) radical (scavenging IC₅₀: 70.9 μM), and superoxide anion radical (inhibition percentage: 48.4 %). Additionally, electrophysiological results showed that compound 11c demonstrated potent inhibitory effects on abnormal electrical discharges. Furthermore, compound 11c displayed the capacity to relieve H₂O₂-induced oxidative damage and LPS-induced neuroinflammation at the cellular level. Besides, compound 11c could cross the blood-brain barrier, alleviate the symptoms of epilepsy induced by pentylenetetrazole and pilocarpine effectively, and mitigate oxidative damage caused by sodium nitrite in mice. Therefore, compound 11c possesses symptomatic-treatment and disease-modification properties for epilepsy. These results highlighted that compound 11c was a highly promising candidate for further development as an antiepileptic agent.

2025-08-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Development of isatin-functionalized benzenesulfonamides as novel carbonic anhydrase II and VII inhibitors with antiepileptic potential

Article

作者: Elnaggar, Yosra S R ; Eldehna, Wagdy M ; Giovannuzzi, Simone ; Abo-Ashour, Mahmoud F ; El-Hamaky, Anwar A ; Elsayed, Zainab M ; Al-Sanea, Mohammad M ; Alkabbani, Mahmoud Abdelrahman ; Tawfik, Haytham O ; Nocentini, Alessio ; Supuran, Claudiu T ; Khaleel, Eman F

Epilepsy continues to be a challenging neurological disorder with a partially understood etiology that necessitates novel therapeutic strategies. This study introduces isatin-functionalized benzenesulfonamides (5a-f and 7a-e) targeting carbonic anhydrase (CA) isoforms II and VII implicated in seizure mechanisms. The design exploits a one-tail approach, integrating a sulfonamide warhead for zinc coordination in the CA active site, a triazole linker (inspired by FDA-approved antiepileptic rufinamide), and an isatin-based tail. In vitro evaluation revealed potent inhibition of hCA II and VII, with sulfonamides 5c, 5e, 5f, 7a, and 7d showing notable activity. The anticonvulsant activity of five carbonic anhydrase inhibitors (5c, 5e, 5f, 7a, and 7d) was assessed using PTZ and pilocarpine-induced convulsions in mice. These compounds were selected based on their superior in vitro inhibitory potency against hCA II and VII isoforms, as reflected by their low nanomolar K_I values. Among them, 5e and 7a exhibited the highest efficacy, achieving 100 % protection in the PTZ model and significantly delaying seizure onset in the pilocarpine model. These compounds also reduced seizure severity and improved survival rates, surpassing valproic acid's effectiveness. Additionally, biochemical evaluation revealed that both compounds restored hippocampal KCC2 and mTOR levels, suggesting their role in modulating neuronal excitability and ionic balance. Safety assessments, including Rotarod and biochemical toxicity tests, confirmed their favorable safety profile, supporting their potential as promising anticonvulsant candidates.

2025-07-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Novel benzenesulfonamide derivatives linked to diaryl pyrazole tail as potential carbonic anhydrase II/VII inhibitors with anti-epileptic activity

Article

作者: Mohamed, Mamdouh F A ; Fadaly, Wael A A ; Giovannuzzi, Simone ; Abd El-Hameed, Abeer M ; Nemr, Mohamed T M ; Supuran, Claudiu T ; Eldehna, Wagdy M ; Alkabbani, Mahmoud Abdelrahman ; Nocentini, Alessio ; Zidan, Taha H ; Hefina, Mohamed M

Two new series of 1,2,3-triazole benzenesulfonamide derivatives 16a-f and imino-thiazolidinone benzenesulfonamide derivatives 19a-f with diaryl pyrazole tail were synthesized as carbonic anhydrase (CA) II, VII inhibitors and assessed for antiepileptic activity. All compounds were tested in vitro for their inhibition activity against the human (h) carbonic anhydrase I, II, and VII isoforms. Among these series, compounds 16b, 16d, 19b, and 19d exhibited exceptional inhibitory activity against hCA II, with K_i 10.9-47.1 nM, and hCA VII, with K_i 8.4-23.6 nM, while the two series did not show significant activity against hCA I. Furthermore, 16b, 16d, 19b, and 19d were tested against in vivo pilocarpine-induced seizure model, and they showed excellent neuroprotective activity; they delayed seizure onset, reduced seizure severity, and improved survival rates compared to the pilocarpine group, which highlighted their efficacy in regulating neuronal excitability through CA inhibition and chloride homeostasis. Also, hippocampal levels of KCC2 and mTOR were analyzed, as these markers are critical in regulating neuronal excitability and are closely linked to epilepsy. Noteworthy, Compounds 16d and 19b surpassed the standard anti-convulsant valproic acid in key parameters, underscoring their superior efficacy. In addition, they do not show any significant neurotoxic effects or alterations in liver and kidney function. Moreover, the results of in vitro cytotoxicity of compounds 16d and 19b against Vero cells indicate their safety at the doses given (IC₅₀ = 59.7, 71.9 μM respectively) compared to acetazolamide (IC₅₀ = 32.3 μM). Finally, molecular docking of sulfonamide derivatives with hCA II (PDB code: 2h4h) and hCA VII (PDB code: 3ml5) was performed.

170

项与盐酸毛果芸香碱相关的新闻（医药）

2025-04-14

·GlobeNewswire-Health Care

SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)

DUBLIN, Ireland and OXFORD, United Kingdom, April 14, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to emactuzumab for the treatment of TGCT patients that are not amenable to or who would not benefit from surgery. Emactuzumab, a potentially best-in-class CSF-1 receptor (CSF-1R) inhibiting monoclonal antibody, is currently being evaluated in the TANGENT study, a global, multi-centre, randomized, double-blind, placebo-controlled registrational Phase 3 trial. TGCT is a rare, non-malignant but aggressively growing tumour of the synovium, tendon sheaths and bursa membranes primarily located in knee, hip, and ankle joints and caused by excessive production of CSF-1. It is a chronically debilitating disease for patients causing loss of function of the affected joints, as well as pain, stiffness and limited range of motion. Receipt of FTD for TGCT was supported by data from Phase 1/2 clinical studies demonstrating rapid, robust tumour reduction and durable response combined with a manageable safety profile. Emactuzumab has also previously received Orphan Medicinal Project designation from the European Medicines Agency. “The granting of FTD for emactuzumab in TGCT highlights the devastating toll that this disease has on patients, as well as the critical need that remains for new treatment options,” said Elyse Seltzer, M.D., Chief Medical Officer of SynOx Therapeutics. “Based on our clinical work to date, we believe that emactuzumab has significant potential to address key patient needs by offering an effective, short-course treatment with rapid onset and a durable response that allows individuals suffering from TGCT to better manage their disease and move forward with their lives. We look forward to completing the ongoing TANGENT study and progressing emactuzumab toward potential commercialization.” About Fast Track DesignationThe FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need. Fast Track status allows for enhanced communication and collaboration between the FDA and drug developers, potentially speeding up the delivery of life-saving treatments to patients. About Tenosynovial Giant Cell Tumour (TGCT)Tenosynovial Giant Cell Tumour (TGCT), previously termed pigmented villonodular synovitis (PVNS), is a type of tumour that affects the soft tissue lining of joints and tendons. TGCTs are categorised as fibrohistiocytic tumours by the WHO classification and are subclassified based on growth patterns (localised and diffuse types) and location (tendon sheath, intra- and extra-articular forms). TGCTs are locally destructive and can be aggressive. The disease causes significant joint pain, stiffness, loss of function and reduced quality of life. While most patients undergo surgery, more than 50% of those with diffuse TGCT experience tumour recurrence within three years. If left untreated, TGCT can cause joint deformity, degenerative changes, and even lead to arthrodesis or amputation in severe cases. About CSF-1 and EmactuzumabCSF-1 (or macrophage colony-stimulating factor) is a cytokine that binds to the CSF-1 receptor (CSF-1R), expressed on macrophages and other immune cells. Emactuzumab is a humanised IgG1 monoclonal antibody targeting CSF-1R, designed to inhibit and deplete macrophages in tumour tissue. Originally developed by Roche, emactuzumab has shown substantial efficacy in clinical studies in TGCT, including an objective response rate of ~71%, rapid tumour reduction, functional improvement, and good tolerability with a manageable safety profile. Emactuzumab may also have utility in other macrophage-driven diseases, and SynOx is actively exploring further development opportunities in these areas. Additional details regarding the ongoing registrational Phase 3 TANGENT study can be found on ClinicalTrials.gov (Identifier: NCT05417789). About SynOx TherapeuticsSynOx Therapeutics Limited is a Dublin and Oxford-based, late-stage clinical biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1-related and macrophage-driven disorders. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialization. The company is backed by a strong syndicate of premier life science investors including Forbion, Gilde Healthcare, HealthCap, Bioqube Ventures and Medicxi. Contacts: SynOx Therapeutics Ray Barlow Chief Executive Officer Tel: +44 (0) 208 058 5619 Email: enquiries@synoxtherapeutics.com Vida Strategic Partners (on behalf of SynOx) Tim Brons (Media) 415-675-7402 tbrons@vidasp.com

快速通道临床3期孤儿药

2025-04-13

·蒲公英Ouryao

【出海新进展】4药品出口海外！

来源：企业公告编辑：wangxinglai2004近日，四药企分别发布了产品海外上市进展公告，具体为甘李药业制剂获巴基斯坦注册批件、浙江奥翔药业原料药获CEP证书、健友生化制剂获FDA批件和浙江东邦药业原料药获韩国注册证书。甘李药业制剂获巴基斯坦注册批件一、药物基本情况药品名称：BASAGINE 药品通用名：甘精胰岛素注射液适应症：糖尿病剂型：注射剂规格：3ml：100IU/ml（卡式瓶）批件号：Reg. No. 120504申请人：甘李药业股份有限公司二、药物其他相情况甘精胰岛素注射液属于长效胰岛素类似物产品，又称基础胰岛素类似物，每天注射一次，注射起效后作用时间可持续24小时。甘精胰岛素具有作用时间长、血药浓度无峰值、平稳地降低患者血糖的作用，有较好的疗效和安全性，因此甘精胰岛素注射液成为糖尿病治疗中尤为重要的基础胰岛素类似物。截至公告发布日，在巴基斯坦境内甘精胰岛素注射液的主要供货商为赛诺菲。赛诺菲作为原研厂家，其甘精胰岛素产品2024年的全球销售额约17.6 亿美元，截至2024 年9月30日，甘李药业在甘精胰岛素项目中累计投入研发费用9.06亿元人民币。浙江奥翔药业原料药获CEP证书一、药物基本情况药品名称：盐酸毛果芸香碱剂型：原料药持有人：浙江奥翔药业股份有限公司证书编号：CEP 2023-367-Rev 00 发证机构：欧洲药品质量管理局（EDQM）二、药物其他相情况盐酸毛果芸香碱最早用于治疗口干症，剂型为片剂。随后盐酸毛果芸香碱被开发为其它剂型，如凝胶剂、滴眼液等，用于治疗开角型青光眼、闭角型青光眼以及高眼压症等。 2021年，艾伯维（Abbvie）旗下公司艾尔建研制的盐酸毛果芸香碱滴眼液（规格1.25%）获美国FDA批准上市，是全球首款用于治疗老视的药物。盐酸毛果芸香碱是M-胆碱受体激动剂，可激活平滑肌的毒蕈碱受体，通过虹膜括约肌的收缩，使瞳孔收缩，以增加焦深，改善近中视力，同时保持瞳孔对光的反应，另外其还可收缩睫状肌，增强适应力，从而达到治疗成人老视的效果。健友生化制剂获FDA批件一、药物基本情况药品名称：利拉鲁肽注射液适应症：作为饮食和运动的辅助手段，改善成人和10岁及以上的儿童2型糖尿病患者的血糖控制。降低伴有心血管疾病的2型糖尿病成人患者的主要心血管不良事件的风险。剂型：注射液规格：18 mg/3 mL (6 mg/mL) ANDA号：218115 申请人：南京健友生化制药股份有限公司二、药物其他相情况利拉鲁肽注射液原研药品，由NOVO NORDISK INC持有，2010年01月25日前经FDA批准在美国上市。经查询，除原研厂家以外，美国境内仅有1家HIKMA PHARMACEUTICALS USA INC同规格的利拉鲁肽注射液获批上市。截至目前公司在利拉鲁肽注射液研发项目上已投入研发费用约人民币5,737.31万元。浙江东邦药业原料药获韩国注册证书一、药物基本情况企业名称：浙江东邦药业有限公司地址：中国浙江省台州市临海市台州湾经济技术开发区东海第五大道21号产品名称：头孢妥仑匹酯 DMF注册号：20250326-209-J-1841 发证机构：韩国食品药品监督管理局（韩国MFDS）二、药物其他相情况头孢妥仑匹酯为第三代头孢类抗菌药物，用于治疗敏感菌引起的呼吸道、泌尿系统、胆道、皮肤软组织感染等。据相关数据显示，2023年度头孢妥仑匹酯制剂全国销售额约为1.36亿元。

上市批准

2025-04-07

·信狐药迅

抗精神病改良新布瑞哌唑口溶膜，第五家南通慧聚提交上市申请|新受理（3.24-3.30）

本周药品注册受理数据，分门别类呈现，一目了然。(3.24-3.30）新药上市申请药品名称企业注册分类受理号布瑞哌唑口溶膜南通慧聚制药有限公司2.2CXHS2500026布瑞哌唑口溶膜南通慧聚制药有限公司2.2CXHS2500025新药临床申请药品名称企业注册分类受理号DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500342DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500341DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500340AOD113408注射液成都奥达生物科技有限公司1CXHL2500339EDP167注射液亿腾医药(珠海)有限公司1CXHL2500336VVN432鼻喷雾剂维眸生物科技(浙江)有限公司1CXHL2500335VVN432鼻喷雾剂维眸生物科技(浙江)有限公司1CXHL2500334CPI-818片嘉兴和剂药业有限公司1CXHL2500332CPI-818片嘉兴和剂药业有限公司1CXHL2500331WJ47156片上海君实生物医药科技股份有限公司1CXHL2500330WJ47156片上海君实生物医药科技股份有限公司1CXHL2500329JKN2301干混悬剂健康元药业集团股份有限公司1CXHL2500327BW-40202注射液上海舶望制药有限公司1CXHL2500338RO7673396薄膜包衣片罗氏研发(中国)有限公司1CXHL2500325RO7673396薄膜包衣片罗氏研发(中国)有限公司1CXHL2500324RO7673396薄膜包衣片罗氏研发(中国)有限公司1CXHL2500323WSD0922-FU片杭州威瑞宝生物医药有限公司1CXHL2500322WSD0922-FU 片杭州威瑞宝生物医药有限公司1CXHL2500321JZ-14胶囊云白药征武科技(上海)有限公司1CXHL2500320JZ-14胶囊云白药征武科技(上海)有限公司1CXHL2500319SVHRSP注射液沈阳万锦医药科技有限公司1CXHL2500318Alpha-0261片深圳阿尔法分子科技有限责任公司1CXHL2500316Alpha-0261片深圳阿尔法分子科技有限责任公司1CXHL2500315AKZ002直服颗粒海南爱科制药有限公司2.2CXHL2500343WS-011湖北午时药业股份有限公司2.2CXHL2500337ZL-0018山东则正医药技术有限公司2.2CXHL2500328硫酸镁无菌溶液广东迈恒医药研发有限公司2.2CXHL2500326EP-0203XR成都苑东生物制药股份有限公司2.3CXHL2500333注射用甲苯磺酸瑞马唑仑江苏恒瑞医药股份有限公司2.4CXHL2500317注射用JS207上海君实生物医药科技股份有限公司1CXSL2500252HD006细胞华道(上海)生物医药有限公司1CXSL2500251Cizutamig注射液上海坦蒂生物医药科技有限公司1CXSL2500249注射用人白介素-2(高亲和型复合物)北京良远生物医药研究有限公司1CXSL2500248注射用SSGJ-705沈阳三生制药有限责任公司1CXSL2500247注射用BC2027无锡智康弘义生物科技有限公司1CXSL2500245注射用TQB2102正大天晴药业集团南京顺欣制药有限公司1CXSL2500241AZD0901阿斯利康全球研发(中国)有限公司1CXSL2500242注射用MK-2870默沙东研发(中国)有限公司2.2CXSL2500244注射用重组A型肉毒毒素北京博特维克生物技术有限公司2.4CXSL2500246仿制药申请药品名称企业注册分类受理号马来酸曲美布汀片浙江东亚药业股份有限公司3CYHS2501232马来酸曲美布汀片浙江东亚药业股份有限公司3CYHS2501231厄贝沙坦氨氯地平片(III)浙江昂利康制药股份有限公司3CYHS2501230维生素B6注射液湖南先施制药有限公司3CYHS2501229厄贝沙坦氨氯地平片(I)浙江昂利康制药股份有限公司3CYHS2501228重酒石酸卡巴拉汀口服液海南海和制药有限公司3CYHS2501227重酒石酸卡巴拉汀口服液海南海和制药有限公司3CYHS2501226盐酸依匹斯汀滴眼液参天制药(中国)有限公司3CYHS2501218法莫替丁注射液山西铭羽生物科技有限公司3CYHS2501216法莫替丁注射液山西铭羽生物科技有限公司3CYHS2501215维生素B6注射液西洲医药科技(浙江)有限公司3CYHS2501201琥珀酸亚铁片山西同达药业有限公司3CYHS2501200琥珀酸亚铁片上海金不换兰考制药有限公司3CYHS2501199布美他尼注射液重庆博腾药业有限公司3CYHS2501196吡格列酮二甲双胍片上海青平药业有限公司3CYHS2501195罗沙司他片石家庄市华新药业有限责任公司3CYHS2501188盐酸伊立替康脂质体注射液石药集团欧意药业有限公司3CYHS2501187复方聚乙二醇电解质散(儿童型)福州基石医药科技有限公司3CYHS2501182硝普钠注射液中润药业有限公司3CYHS2501180硝普钠注射液山西九康医药科技有限公司3CYHS2501176硝普钠注射液海南海和制药有限公司3CYHS2501159比拉斯汀口服溶液湖南科伦制药有限公司3CYHS2501158盐酸丁螺环酮片浙江京新药业股份有限公司3CYHS2501157盐酸丁螺环酮片浙江京新药业股份有限公司3CYHS2501156山梨醇甘露醇冲洗剂西安京西双鹤药业有限公司3CYHS2501155铝碳酸镁混悬液江苏润恒制药有限公司3CYHS2501173盐酸精氨酸注射液四川邈济生物医药科技有限公司3CYHS2501162碳酸氢钠注射液安徽双鹤药业有限责任公司3CYHS2501161注射用吲哚菁绿仁合益康汇泽药业河北有限公司3CYHS2501160聚多卡醇注射液苏州朗科生物技术股份有限公司4CYHS2501225聚多卡醇注射液苏州朗科生物技术股份有限公司4CYHS2501224聚多卡醇注射液苏州朗科生物技术股份有限公司4CYHS2501223甲磺酸溴隐亭片江苏诚康药业有限公司4CYHS2501222乌帕替尼缓释片复星万邦(江苏)医药集团有限公司4CYHS2501221乌帕替尼缓释片复星万邦(江苏)医药集团有限公司4CYHS2501220乌帕替尼缓释片复星万邦(江苏)医药集团有限公司4CYHS2501219盐酸尼卡地平注射液国药集团容生制药有限公司4CYHS2501217注射用氟氧头孢钠齐鲁安替制药有限公司4CYHS2501214注射用氟氧头孢钠齐鲁安替制药有限公司4CYHS2501213盐酸托莫西汀口服溶液山东步长制药股份有限公司4CYHS2501212利多卡因凝胶贴膏南京海纳医药科技股份有限公司4CYHS2501211双氯芬酸二乙胺乳胶剂湖南九典制药股份有限公司4CYHS2501210苯磺酸左氨氯地平片河南普瑞药业有限公司4CYHS2501209苯磺酸左氨氯地平片河南普瑞药业有限公司4CYHS2501208硫酸氨基葡萄糖胶囊山东诚康药业有限公司4CYHS2501207棕榈酸帕利哌酮注射液石药集团中诺药业(石家庄)有限公司4CYHS2501206棕榈酸帕利哌酮注射液石药集团中诺药业(石家庄)有限公司4CYHS2501205棕榈酸帕利哌酮注射液石药集团中诺药业(石家庄)有限公司4CYHS2501204比拉斯汀片桂林南药股份有限公司4CYHS2501203阿帕他胺片成都倍特药业股份有限公司4CYHS2501202舒更葡糖钠注射液海南斯达制药有限公司4CYHS2501198妥布霉素滴眼液深圳大佛药业股份有限公司4CYHS2501197硫酸氨基葡萄糖胶囊南京海鲸药业股份有限公司4CYHS2501194骨化三醇注射液山西康成利安医药有限公司4CYHS2501193地夸磷索钠滴眼液广东恒健制药有限公司4CYHS2501192硫酸氨基葡萄糖胶囊山东诺禾康药业有限公司4CYHS2501191骨化三醇注射液河南泰丰生物科技有限公司4CYHS2501190达格列净片山东普瑞曼药业有限公司4CYHS2501189艾普拉唑肠溶片浙江高跖医药科技股份有限公司4CYHS2501186阿奇霉素干混悬剂云鹏医药集团有限公司4CYHS2501185氟比洛芬凝胶贴膏湖南金圃医药科技有限公司4CYHS2501184布洛芬缓释胶囊郑州泰丰制药有限公司4CYHS2501183阿帕他胺片正大天晴药业集团南京顺欣制药有限公司4CYHS2501181沙库巴曲缬沙坦钠片海南赛立克药业有限公司4CYHS2501179沙库巴曲缬沙坦钠片海南赛立克药业有限公司4CYHS2501178沙库巴曲缬沙坦钠片海南赛立克药业有限公司4CYHS2501177玻璃酸钠滴眼液石家庄四药有限公司4CYHS2501175玻璃酸钠滴眼液石家庄四药有限公司4CYHS2501174阿莫西林克拉维酸钾干混悬剂山东益康药业股份有限公司4CYHS2501154黄体酮软胶囊深圳大佛药业股份有限公司4CYHS2501171黄体酮软胶囊深圳大佛药业股份有限公司4CYHS2501170乳果糖口服溶液湖北午时药业股份有限公司4CYHS2501168蛋白琥珀酸铁口服溶液中山百灵生物技术股份有限公司4CYHS2501167八氟丙烷脂质微球注射液广州康臣药业有限公司4CYHS2501166硫酸镁钠钾口服用浓溶液湖北午时药业股份有限公司4CYHS2501165富马酸伏诺拉生片蚌埠丰原涂山制药有限公司4CYHS2501164富马酸伏诺拉生片蚌埠丰原涂山制药有限公司4CYHS2501163乌帕替尼缓释片上海信谊百路达药业有限公司4CYHS2501172硫酸氨基葡萄糖胶囊江苏诺泰澳赛诺生物制药股份有限公司4CYHS2501169破伤风人免疫球蛋白浙江海康生物制品有限责任公司3.4CXSS2500038盐酸达克罗宁局部溶液剂深圳珐玛易药品科技有限公司3CYHL2500073溴莫尼定凝胶深圳珐玛易药品科技有限公司3CYHL2500072酮洛芬贴剂北京福元医药股份有限公司3CYHL2500071酮洛芬贴剂北京福元医药股份有限公司3CYHL2500070盐酸毛果芸香碱滴眼液苏州欧康维视生物科技有限公司3CYHL2500067米诺地尔泡沫剂深圳珐玛易药品科技有限公司3CYHL2500066双氯芬酸依泊胺贴深圳珐玛易药品科技有限公司3CYHL2500065硝呋太尔制霉菌素阴道软胶囊山东华铂凯盛生物科技有限公司4CYHL2500069沙美特罗替卡松吸入粉雾剂杭州知兴制药有限公司4CYHL2500068吸附破伤风疫苗北京智飞绿竹生物制药有限公司3.3CXSL2500250流感病毒裂解疫苗陕西昆秦生物科技有限公司3.3CXSL2500243进口申请药品名称企业注册分类受理号艾伏尼布片Servier Pharmaceuticals LLC5.1JXHS2500042利多卡因丙胺卡因气雾剂PLETHORA SOLUTIONS LIMITED5.1JXHS2500041度伐利尤单抗注射液AstraZeneca UK Limited3.1JXSS2500038度伐利尤单抗注射液AstraZeneca UK Limited3.1JXSS2500037PF-07985045片Pfizer Inc.1JXHL2500066PF-07985045片Pfizer Inc.1JXHL2500065Orforglipron胶囊Eli Lilly and Company1JXHL2500064Orforglipron胶囊Eli Lilly and Company1JXHL2500063Orforglipron胶囊Eli Lilly and Company1JXHL2500062Orforglipron胶囊Eli Lilly and Company1JXHL2500061Orforglipron胶囊Eli Lilly and Company1JXHL2500060Orforglipron胶囊Eli Lilly and Company1JXHL2500059TPST-1120片Tempest Therapeutics, Inc.1JXHL2500058Golcadomide胶囊Celgene Corporation1JXHL2500055Golcadomide胶囊Celgene Corporation1JXHL2500054Golcadomide胶囊Celgene Corporation1JXHL2500053Golcadomide胶囊Celgene Corporation1JXHL2500052醋酸甲地孕酮口服混悬液TWi Pharmaceuticals, Inc.2.4JXHL2500056罗氟司特泡沫Arcutis Biotherapeutics INC5.1JXHL2500057Empasiprubart注射用浓溶液argenx BV1JXSL2500047DS-1062aASTRAZENECA AB1JXSL2500045AZD2936AstraZeneca AB1JXSL2500044AZD2936AstraZeneca AB1JXSL2500042仑卡奈单抗注射液(皮下注射)Eisai Co., Ltd.2.1JXSL2500046TarlatamabAmgen Inc.2.2JXSL2500041TarlatamabAmgen Inc.2.2JXSL2500040TarlatamabAmgen Inc.2.2JXSL2500039帕博利珠单抗注射液Merck Sharp & Dohme LLC2.2JXSL2500043中药相关申请药品名称企业注册分类受理号桃核承气汤颗粒合肥华润神鹿药业有限公司3.1CXZS2500012肺热咳喘颗粒海南葫芦娃药业集团股份有限公司2.3CXZL2500020注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市临床申请

100 项与盐酸毛果芸香碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02200	盐酸毛果芸香碱	S01EB01 N07AX01	DB01085

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
老花眼	美国	AbbVie, Inc.	2021-10-28
急性闭角型青光眼	美国	Sandoz, Inc.	2010-06-22
高眼压症	美国	Alcon Laboratories, Inc.	1984-10-01
口干症	加拿大	Alcon Canada, Inc.	1951-12-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干燥综合征性角膜结膜炎	临床2期	美国	Glaukos Corp.	2022-01-03
干眼症	临床2期	美国	Glaukos Corp.	-
瞳孔缩小	临床1期	美国	Novus Vision LLC	2025-01-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04599933 (NEAR-1, CTgov)	临床3期	老花眼	309	CSF-1 (CSF-1)	觸餘蓋獵鹹蓋築簾獵齋 = 獵選獵顧醖餘壓壓餘淵顧憲壓獵製襯齋廠憲鏇 (築範餘繭膚廠襯鏇鏇膚, 範積遞衊鬱艱膚齋繭鏇 ~ 積夢醖築顧窪衊憲願糧) 更多	-	2023-11-28
				Vehicle (Vehicle)	觸餘蓋獵鹹蓋築簾獵齋 = 繭簾願蓋鬱膚製襯襯糧顧憲壓獵製襯齋廠憲鏇 (築範餘繭膚廠襯鏇鏇膚, 襯糧顧網繭憲淵鏇繭憲 ~ 醖鑰齋壓構醖廠鹹憲願) 更多
NCT04599972 (NEAR-2, CTgov)	临床3期	老花眼	304	CSF-1 (CSF-1)	範鑰齋繭鏇衊膚糧簾夢 = 選獵壓遞觸衊製獵壓製製構衊醖壓簾憲窪醖觸 (觸願壓蓋繭窪鏇獵選選, 壓範糧鹽淵積齋糧餘衊 ~ 鬱選願觸鏇製夢壓鬱艱) 更多	-	2023-11-28
				Vehicle (Vehicle)	範鑰齋繭鏇衊膚糧簾夢 = 餘鏇糧製膚網糧遞衊鬱製構衊醖壓簾憲窪醖觸 (觸願壓蓋繭窪鏇獵選選, 積網繭齋網鏇膚範憲糧 ~ 膚獵鏇夢觸窪餘鹹積構) 更多
NCT04675151 (CTgov)	临床2期	老花眼	150	LDP+POS (POS 0.75% First, Then LDP 0.4%)	衊壓獵願醖構餘鬱窪鹹 = 糧選膚衊簾壓製願窪願獵糧願蓋鑰艱製顧醖醖 (製醖觸願夢淵壓構鏇襯, 網範齋遞鬱窪糧繭淵鬱 ~ 範鹽醖獵築鹽獵餘繭襯) 更多	-	2023-08-02
				LDP+POS (POS 0.75% First, Then LDP Vehicle)	衊壓獵願醖構餘鬱窪鹹 = 糧願積壓築繭淵觸糧積獵糧願蓋鑰艱製顧醖醖 (製醖觸願夢淵壓構鏇襯, 憲膚壓壓範築鑰獵廠鑰 ~ 衊遞鹹衊願觸襯廠夢願) 更多
GEMINI (ARVO2023)	临床3期	老花眼	750	Pilocarpine HCl ophthalmic solution 1.25%	艱網壓鏇蓋窪鹹鬱窪構(糧選襯簾遞顧積鬱餘遞) = 願構鏇鹹鏇淵糧憲艱襯廠齋顧鹽鏇憲繭獵醖壓 (餘繭窪範衊範窪鑰觸淵 ) 更多	-	2023-06-01
				Vehicle	艱網壓鏇蓋窪鹹鬱窪構(糧選襯簾遞顧積鬱餘遞) = 淵淵築製窪壓遞繭鹹襯廠齋顧鹽鏇憲繭獵醖壓 (餘繭窪範衊範窪鑰觸淵 ) 更多
NCT03804268 (GEMINI 1, ARVO2023)	临床3期	老花眼	323	Pilocarpine hydrochloride ophthalmic solution 1.25%	範窪構鏇範鏇築鬱簾衊(築衊壓憲範齋憲選衊淵) = 醖範夢獵願構壓願獵壓簾蓋願膚衊積憲壓糧鹹 (鏇醖鬱夢鬱鑰淵窪構憲 )	-	2023-04-23
				Vehicle	範窪構鏇範鏇築鬱簾衊(築衊壓憲範齋憲選衊淵) = 獵鑰壓遞齋憲範淵網齋簾蓋願膚衊積憲壓糧鹹 (鏇醖鬱夢鬱鑰淵窪構憲 )
VEGA-1 (ARVO2023)	临床2期	老花眼	150	0.75% Phentolamine Ophthalmic Solution (POS)	製鹹願憲繭簾獵繭廠遞(築夢網壓繭繭觸繭齋鏇) = 製窪築衊積積淵艱繭鹽夢鹽簾顧鑰窪糧選觸膚 (願顧膚襯襯齋觸築鑰製 )	积极	2023-04-23
				0.4% Low Dose Pilocarpine (LDP)	製鹹願憲繭簾獵繭廠遞(築夢網壓繭繭觸繭齋鏇) = 獵齋襯鏇顧觸範觸選醖夢鹽簾顧鑰窪糧選觸膚 (願顧膚襯襯齋觸築鑰製 )
NCT05238233 (CTgov)	临床4期	瞳孔不等	11	Reichert phoropter+Proparacaine Hydrochloride+Tropicamide+1% Pilocarpine	廠膚鬱淵廠顧簾憲廠選 = 窪憲構醖築壓獵憲艱範網遞築夢淵膚範夢衊繭 (積獵鑰鹹淵繭廠觸蓋鏇, 淵餘範製簾觸衊遞襯鏇 ~ 選觸餘鑰餘鹽鏇鬱鑰願) 更多	-	2023-03-07
NCT03885011 (CTgov)	临床2期	老花眼	166	pilocarpine HCl+diclofenac Na (CSF-1-FDC)	蓋襯壓鏇鏇蓋繭鏇鹹艱 = 衊獵艱糧顧簾積壓繭齋網範餘餘膚糧壓鑰廠網 (鏇衊獵遞襯鬱夢鹹鹽膚, 膚齋積醖願淵鑰遞選鏇 ~ 餘構獵繭鹹壓膚膚構範) 更多	-	2023-01-26
				pilocarpine HCl (Pilo)	蓋襯壓鏇鏇蓋繭鏇鹹艱 = 夢壓蓋遞積構夢願糧餘網範餘餘膚糧壓鑰廠網 (鏇衊獵遞襯鬱夢鹹鹽膚, 淵襯壓夢醖鹽鹹夢夢夢 ~ 夢鹽獵夢積襯醖襯窪廠) 更多
NCT04657172 (VISION-2, Biospace) 人工标引	临床3期	老花眼	-	pilocarpine	鑰憲廠夢積選觸繭膚遞(衊製鹹窪顧鬱憲積製網) = VISION-2 met its primary endpoint with a statistically significant proportion of subjects treated with MicroLine showing a 15-letter or more improvement in distance corrected near visual acuity (DCNVA) with less than a 5-letter loss in distance acuity versus placebo in low light conditions at two hours post-treatment. 窪醖膚鑰憲鹽築構餘繭 (鏇選窪鬱願網齋網壓繭 ) 更多	积极	2022-10-20
				Placebo
GEMINI 1 and GEMINI 2 (AAO2022)	N/A	-	750	Pilocarpine HCl ophthalmic solution 1.25%	醖簾鹹鹽獵衊製遞鏇顧(膚窪鹽積觸窪襯鏇築構) = 範鏇壓憲廠蓋夢壓襯觸鑰壓醖衊鑰壓齋醖積繭 (鹽膚襯製壓蓋構獵壓網 )	-	2022-09-29
				Vehicle control	醖簾鹹鹽獵衊製遞鏇顧(膚窪鹽積觸窪襯鏇築構) = 觸觸齋膚構艱餘糧觸夢鑰壓醖衊鑰壓齋醖積繭 (鹽膚襯製壓蓋構獵壓網 )